L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.
PKvitality is developing K'Watch Glucose, a painless Continuous Glucose Monitoring device in a form of a smartwatch. Completely invisible to others, K'Watch will help diabetics to better control their disease and check their glucose level discreetly.
Paris, Île-de-France, France
Envoyer un message
French medtech companies are tackling diabetes and innovating, as proven by the sheer number of patents filed in 2021. Each year, the National Industrial Property Institute (INPI)ranks the top patent filers, highlighting companies that invest in innovation. The French startup PKvitality, specializing in Health and Sport Biowearables, is a new entrant to the prestigious ranking with the K'Watch Glucose, the first Continuous Glucose Monitor (CGM) in the form of a smartwatch, aimed at changing the daily life of millions of diabetes patients. The company, a leader in diabetes innovation, joins a ranking that includes companies from the transport sector in the top three: Safran, Stellantis and the Valeo Group.
39 patents to monitor diabetes, without gestures or pain! Founded in 2013, PKvitality is one of the most promising French medtech companies to join the INPI ranking in the SME category. At the intersection of medical devices and consumer electronics, PKvitality is developing the K'Watch Glucose: a painless, accurate and discreet glucose monitoring smartwatch. With 39 patents filed, it incorporates several innovations for the benefit of patients:
● No pain thanks to the SkinTaste technology, based on micro-pins (<1mm long)
● Integration of a soft and resistant adhesive, thanks to the watch strap that holds the patch in place and protects it from shocks
● An ultra-discreet device with the patch hidden behind the watch, access to blood glucose data directly on the screen and the ability to receive hypoglycemia and hyperglycemia alerts with a simple vibration on the wrist
According to Luc Pierart, founder of PKvitality, "Our ambition is to offer diabetes patients a technological innovation that becomes a part of their daily life. Despite the challenges, nothing is impossible! We have succeeded in developing a reliable, discreet, and painless product, at the intersection of medtech and consumer electronics. Such an innovation must be protected in an extremely competitive world, which is why we have filed 39 patents to protect our concept with the INPI and the EPO (European Patent Office). We hope that K'Watch will change the daily life of millions of diabetics! ".
Clinical studies on humans that demonstrate its success Last May, at the ATTD trade show in Barcelona, PKvitality unveiled the results of its first clinical study on humans. The measurement of glucose levels for patients with type 1 and type 2 diabetes is a demanding process in terms of accuracy, tolerance, and pain. Based on these criteria, the study conducted by PKvitality was a success, demonstrating an excellent user experience and high accuracy of the device. The trial took place at the AMCR Institute, a clinical research center specializing in diabetes and obesity, and of renown with regards to medical devices related to metabolism. Other clinical studies on humans are ongoing. PKvitality has also joined the largest e-health accelerator in Europe, Future4Care.
PKvitality, has been selected to join the 1st promotion of Future4care, the largest eHealth accelerator in Europe. At the forefront of diabetes innovation, PKvitality has developed K’Watch Glucose, the world’s first Continuous Glucose Monitoring (CGM) smartwatch. The acceleration will speed up the development of this unique innovation in diabetes monitoring that takes the form of a smartwatch.
Future4care is Europe’s largest open-innovation ecosystem on healthcare created under the initiative of four leading companies: Capgemini, Generali, Orange, and Sanofi. Its ambition is to support emerging companies in bringing their solutions to market and to accelerate future of healthcare for patients, by making the most of the possibilities of digital technology.
Visit the K’Watch Glucose to learn more.
PKvitality officially attended Europe’s most anticipated conference on Advanced Technologies and Treatments for Diabetes (ATTD) – from April 27-30, 2022, in Barcelona.
On this occasion, the results of the First-In-Human Clinical Trials of K’Watch Glucose have been presented in an e-poster by Timothy Bailey, Principal Investigator of the trial and CEO of AMCR Institute. These clinical results will be explained, on-site, by Minh Lê, General Manager of PKvitality.
The trials led by PKvitality were successful and showed great user experience and tracking. The trial took place at AMCR Institute, a clinical research center focused on diabetes and obesity with worldwide renowned medical device expertise in the metabolic area. Non-invasive, precise and affordable, K’Watch will change the everyday lives of diabetics!
Munich, 28 April 2021 - Among the 160 start-up candidates, PKvitality is one of the 5 start-ups to have been awarded. PKvitality was co-winner of the 12th edition of the IoT Innovation World Cup in the medical category. The IoT Innovation World Cup is a global competition that brings together over 600 start-ups for a competition based on technological innovation.
Paris, November 23, 2020 - PKvitality was rewarded by being named the world’s No. 1 “Internet of Medical Things Techpreneurs 2020” at the 12th Healthcare Innovation World Cup 2020 held during the Medica exhibition. It was at the Medica Connected Healthcare Forum that PKvitality was able to stand out among more than 120 competing solutions from around the world.
Débute le 2016
First results of in vivo tests on pigs
CES presence: 6 awards including 1 BEST OF INNOVATION in "Tech for a better world" category
Laureate EIC accelerator, blended financing (2.3m€ grant, 5m€ equity)
First in Human results proving high accuracy and excellent tolerance